Skip to main content
. 2020 Dec 10;2020:4716793. doi: 10.1155/2020/4716793

Table 2.

Performances of biomarkers in lung cancer diagnosis.

Biomarkers Sensitivity Specificity PPV NPV AUC (95% CI)
CYFR21 0.735 0.732 0.824 0.619 0.806 (0.743-0.859)
CEA 0.654 0.827 0.817 0.669 0.797 (0.741-0.845)
NSE 0.444 0.757 0.757 0.444 0.597 (0.525-0.665)
SCC 0.192 0.848 0.862 0.426 0.579 (0.511-0.645)
CA125 0.400 0.879 0.833 0.493 0.661 (0.598-0.720)
CA15-3 0.371 0.951 0.920 0.500 0.703 (0.642-0.759)
CA199 0.190 0.915 0.786 0.478 0.503 (0.439-0.567)
CA50 0.063 0.988 0.889 0.411 0.572 (0.494-0.651)
CA242 0.095 0.871 0.522 0.394 0.570 (0.492-0.649)
CA724 0.157 0.941 0.800 0.428 0.583 (0.507-0.660)
The panel 1 0.894 0.619 0.724 0.839 0.854 (0.791-0.904)
The panel 2 0.955 0.576 0.716 0.919 0.875 (0.815-0.921)
The panel 3 0.598 0.730 0.725 0.604 0.776 (0.705-0.837)
The panel 4 0.955 0.525 0.692 0.912 0.884 (0.825-0.928)

PPV: positive predictive value; NPV: negative predictive value; Pane l = CYFR21, CEA, NSE, and SCC; panel 2 = CYFR21, CEA, NSE, SCC, CA125, and CA15-3; panel 3 = CA125, CA15-3, CA19-9, CA50, CA242, and CA724; panel 4 = CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724.